Carl Zeiss Meditec share: Analysts are optimistic.

Last Updated: 17. Januar 2024By

The Carl Zeiss Meditec share has started the new stock year very well and has gained around 9 percent since the second week. Since then, the share has also been trading above the 100 euro mark (as of January 17, 2024, around 10 am).

Although the prices from 2021 are still far away, the outlook for the company’s shares is generally positive after the overall solid conclusion of the 2022/2023 fiscal year. Most recently, 2 fresh and optimistic analyses supported the Carl Zeiss Meditec share.

Carl Zeiss Meditec looks positively towards 2024 With sales of around 2.09 billion euros in the 2022/2023 fiscal year (as of September 2023), the MDAX company has almost reached its own forecast from last summer and exceeded the previous year’s value by around 10 percent. With an EBIT of 348 million euros, Carl Zeiss Meditec remained below the previous year’s level (397 million euros).

Correspondingly, the margin of just under 17 percent only met the lower end of the forecast range of 17 to 20 percent. The company cited an unfavorable product mix and higher strategic investment costs as reasons for the margin decline.

The company’s management is cautiously optimistic for the current year. The EBIT could remain at a similar level as in the 2023/2024 fiscal year – in the medium term, however, the goal is to „sustainably stabilize the EBIT margin above 20 percent“.

Carl Zeiss Meditec share: Analysts are positive at the start of the year The current fiscal year could be an exciting one for the Carl Zeiss Meditec share. The figures for the first quarter are expected in early February, and a more detailed outlook is also possible at this time. In general, the company has very good growth prospects – at least in the long term.

In the short term, analysts are not completely in agreement. However, last week, Hauck & Aufhäuser showed initial optimism and confirmed the price target for the Carl Zeiss Meditec share at 140 euros. UBS also recently upgraded the share of the MDAX company (from „Neutral“ to „Buy“) and significantly raised the price target from 89 to 125 euros.